ArticleJournal of cosmetic dermatology2025
Recombinant Type III Humanized Collagen Solution for Injection Promotes Skin Repair in Chinese Population: A Case Series.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effectiveness and Safety of Recombinant Type III Humanized Collagen Solution Injection Combined With Collagen-III Multi-Peptide Serum in Improving Signs of Photoaging: A Prospective, Split-Face Controlled Clinical Trial.Journal of cosmetic dermatology · 2026Trial
- Age-Associated Differences in Facial Skin Structure in Chinese Women: a Cross-Sectional Study.Dermatology and therapy · 2026Article
- Recombinant humanized type VII collagen for skin repair and regeneration: prospects for reconstructing the dermal-epidermal junction.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFacial erythema and acne scarring are common skin conditions that significantly impair quality of life, necessitating effective treatment options, particularly in Asian populations.
aimsTo evaluate the efficacy and safety of intradermal injections of recombinant type III humanized collagen (RhCol-III) solution for alleviating facial erythema, improving skin texture associated with acne scarring, and evening out skin tone issues associated with post-inflammatory hyperpigmentation (PIH) from acne while also searching for potential underlying anti-inflammatory mechanisms of the RhCol-III solution.
methodsThis case series included six Chinese participants with Fitzpatrick phototypes III/IV, presenting with facial erythema and/or acne scarring. Participants received intradermal injections of 2 mg/mL RhCol-III solution at baseline, 30- and 60- days post-baseline. Clinical evaluations were conducted using VISIA photography and self-assessed Global Aesthetic Improvement Scale (GAIS) scores. Additionally, in vitro testing was performed using the U937 cell line with lipopolysaccharide (LPS) induction to assess the anti-inflammatory effects of the RhCol-III solution on tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) secretion.
resultsAll participants demonstrated a reduction in facial erythema post-treatment, with significant improvements noted in the zygomatic area. The mean erythema area decreased by 49.3% after 90 days. One case with acne scarring showed visible improvement in scar appearance, skin tone, and texture. Moreover, 0.10 mg/mL RhCol-III solution significantly reduced TNF-α and IL-6 levels in vitro by up to 47.75% and 44.96%, respectively.
conclusionRhCol-III solution injections effectively reduced facial erythema and have the potential to improve acne scarring via reduction in the extent of PIH in this series of Chinese cases. The treatment was well-tolerated, with no significant adverse effects. These findings suggest RhCol-III solution as a promising therapeutic option for skin repair and inflammation reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.